Susan Moran
Directeur/Bestuurslid bij BIOATLA, INC.
Vermogen: - $ op 30-04-2024
Actieve functies van Susan Moran
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BIOATLA, INC. | Directeur/Bestuurslid | 01-12-2020 | - |
Independent Dir/Board Member | 01-12-2020 | - | |
TYRA BIOSCIENCES, INC. | Directeur/Bestuurslid | 07-05-2024 | - |
Independent Dir/Board Member | 07-05-2024 | - |
Loopbaan van Susan Moran
Eerdere bekende functies van Susan Moran
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
RAYZEBIO, INC. | Hoofd Techniek/Wetenschap/O&O | 01-07-2021 | 01-05-2024 |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Hoofd Techniek/Wetenschap/O&O | 01-03-2018 | 01-06-2021 |
PUMA BIOTECHNOLOGY, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2014 | 01-02-2018 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Hoofd Techniek/Wetenschap/O&O | 01-01-2011 | 01-01-2014 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Hoofd Techniek/Wetenschap/O&O | 01-01-2007 | 01-01-2011 |
Opleiding van Susan Moran
University of Virginia | Undergraduate Degree |
University of Pennsylvania Medical Center | Graduate Degree |
Duke University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 10 |
Verenigd Koninkrijk | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 5 |
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Sectoraal
Health Technology | 8 |
Consumer Services | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
BIOATLA, INC. | Health Technology |
PUMA BIOTECHNOLOGY, INC. | Health Technology |
RAYZEBIO, INC. | Health Technology |
TYRA BIOSCIENCES, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Susan Moran
- Ervaring